Approvals in 2019: international review and a new agnostic molecular entity

In 2019, the FDA Oncology Center of Excellence (OCE) approved 11 new drugs and biologic agents, 30 supplemental drug and biologic applications, and four biosimilar applications in oncology. These included two landmark approvals involving collaboration among international regulators as part of OCE Project Orbis, as well as the approval of three novel antibody–drug conjugates.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Food and Drug Administration. Project Orbis. (2019).

  2. 2.

    Food and Drug Administration. The therascreen PIK3CA RGQ PCR Kit - P190001 and P190004. (2019).

  3. 3.

    Food and Drug Administration. Oncology Center of Excellence guidance documents. (2019).

  4. 4.

    Blumenthal, G. M. et al. Real-time oncology review and the assessment aid: increasing review efficiency through standardization and earlier data access. (2018).

  5. 5.

    Usdin, S. FDA to Facilitate Access to Unapproved Drugs. (2018).

Download references


The authors would like to thank Kirsten Goldberg for her assistance with editing this manuscript. FDA does not cite publications because we evaluate the source data and base our approvals on the data that are submitted to the Agency (see Related links).

Author information

Correspondence to Harpreet Singh.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

FDA-approved drugs:

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Singh, H., Blumenthal, G. & Pazdur, R. Approvals in 2019: international review and a new agnostic molecular entity. Nat Rev Clin Oncol 17, 130–131 (2020).

Download citation